Skip to content
Yog Pharma
31 terms

The regulatory and quality terms that come up when you qualify an API source for the US market, in plain language.

503A and 503B
Sections of the Federal Food, Drug, and Cosmetic Act that cover compounding. A 503A pharmacy compounds for individual patients on prescription. A 503B outsourcing facility registers with FDA, follows current good manufacturing practice and can supply without patient-specific prescriptions. Both must use bulk drug substances made at FDA-registered establishments and accompanied by a certificate of analysis.
Active pharmaceutical ingredient (API)
The substance in a medicine that produces its intended effect. FDA calls it the drug substance, and compounders call it a bulk drug substance. Browse the API catalogue
ANDA (Abbreviated New Drug Application)
The application FDA reviews to approve a generic drug. It relies on FDA's earlier finding that the reference listed drug is safe and effective, and shows that the generic has the same active ingredient, strength, dosage form and route, and is bioequivalent.
ASMF (Active Substance Master File)
The European master file for an active substance. The applicant's part is shared with the customer, and the restricted part is seen only by the authorities. It is assessed as part of a marketing application and has no approval of its own. US DMF, CEP and ASMF compared
CAS number
A unique identifier the Chemical Abstracts Service assigns to a chemical substance. Different salts and hydrates of the same drug have different CAS numbers, so the number tells you exactly which form is meant.
CEP (Certificate of Suitability)
A certificate granted by the EDQM after assessing a manufacturer's dossier. It confirms that the European Pharmacopoeia monograph, with any extra tests listed on the certificate, is suitable to control the quality of the substance from that route and site. FDA does not accept it in place of a DMF. US DMF, CEP and ASMF compared
Certificate of analysis (CoA)
The record of test results for one batch, with the acceptance limits, signed and dated by the manufacturer's quality unit. ICH Q7 lists what it must contain. How to read an API certificate of analysis
cGMP (current good manufacturing practice)
The quality standards a drug has to be made under. For APIs the reference is ICH Q7. For finished drugs in the United States it is 21 CFR parts 210 and 211.
Change notification
Advance notice from a source that it plans to change a site, a route of synthesis, a specification or a key supplier. The notice period is set in the quality agreement, because some changes need a supplement to the buyer's application before changed material can be used. How we handle change control
Completeness assessment
FDA's check, under GDUFA, that a Type II API DMF contains what is needed for review. A DMF that has paid its fee and passed is published on FDA's list of DMFs available for reference by generic applications. How a US DMF works in an ANDA
DDP (Delivered Duty Paid)
An Incoterms rule under which the seller delivers the goods to the named place, cleared for import, with duties and taxes paid. The buyer only has to unload.
DMF (Drug Master File)
A confidential submission to FDA with details of how a drug or one of its components is made. A Type II DMF covers a drug substance. FDA does not approve a DMF. It reviews the file when an application references it. How a US DMF works in an ANDA
Elemental impurities
Traces of metals such as palladium, lead or arsenic, which can come from catalysts, equipment or raw materials. ICH Q3D sets permitted daily exposures and asks for a risk assessment.
FEI number
The FDA Establishment Identifier, a number FDA assigns to a facility and uses to track its inspections. It is the surest way to look up a manufacturing site in FDA's databases.
Form 483
The list of observations an FDA investigator leaves with a facility at the end of an inspection, when conditions seen may violate requirements. It is not a final determination, but the site's response and FDA's follow-up show how serious the findings were.
GDUFA (Generic Drug User Fee Amendments)
The law under which industry fees fund FDA's review of generic drugs. For API sources it brought a one-time DMF fee, the completeness assessment and facility fees.
ICH
The International Council for Harmonisation, which brings regulators and industry together to write shared technical guidelines. Q7 covers GMP for APIs, Q3A impurities, Q3C residual solvents, Q3D elemental impurities and M7 mutagenic impurities. Standards we assess against
Import alert
An FDA notice that lets its field staff detain products from a named firm at the border without examining them. Material from a site on import alert may not enter the United States at all.
Letter of authorization (LOA)
The letter a DMF holder sends to FDA allowing the agency to review the DMF in support of a named applicant's submission. The applicant includes a copy in its own application. How the letter of authorization works
Monograph
The pharmacopoeial standard for a substance: its definition, the tests, the methods and the acceptance criteria. USP–NF is the pharmacopoeia recognized in US law, and Ph. Eur. is its European counterpart.
NDSRI
A nitrosamine drug substance-related impurity: a nitrosamine formed from the drug molecule itself, usually at a secondary or tertiary amine. FDA sets recommended intake limits for NDSRIs using a potency categorization approach. Nitrosamine risk assessments
Nitrosamine
A class of compounds, many of them probable human carcinogens, that can form when an amine meets a nitrosating agent. NDMA in valsartan, found in 2018, made nitrosamine risk assessment part of every API qualification. Nitrosamine risk assessments
Polymorph
One of several crystal forms a substance can take. Polymorphs share a chemical formula but can differ in solubility, stability and how they behave in manufacturing, so the form supplied has to match the form the product was developed with.
Quality agreement
A written agreement that sets out each party's quality responsibilities, including change notification, complaint handling, deviations and recall support. It is signed before commercial supply begins. Documents in the qualification file
Reference listed drug (RLD)
The approved brand product that FDA designates for generic applicants to reference and compare against. It is identified in FDA's Orange Book.
Residual solvents
Traces of solvents left from manufacture. ICH Q3C sorts them into three classes by toxicity and sets a limit for each.
Retest date
The date after which an API should be re-examined to confirm it still meets its specification before use. It differs from an expiry date, after which the material should not be used.
Safety data sheet (SDS)
A document in a standard 16-section format covering a chemical's hazards, handling, storage and emergency measures, required under OSHA's Hazard Communication Standard.
Specification
The list of tests, analytical methods and acceptance criteria a batch must meet to be released. It may follow a pharmacopoeial monograph, add tests to it, or be agreed with the customer.
UNII
The Unique Ingredient Identifier, a code FDA's substance registry assigns to each distinct substance. Like a CAS number, it differs between salts and hydrates of the same drug.
Warning letter
A public letter in which FDA tells a firm that it has found significant violations and expects them to be corrected. A warning letter to an API site can hold up approval of applications that reference it.

A term we haven’t covered?

Ask us. If it matters to your filing, it matters to how we put the documents together.

Ask a question